Compare EML & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EML | TVGN |
|---|---|---|
| Founded | 1858 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.9M | 21.3M |
| IPO Year | 1995 | 2021 |
| Metric | EML | TVGN |
|---|---|---|
| Price | $24.91 | $7.31 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.6K | 6.5K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 185.40 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $248,970,345.00 | N/A |
| Revenue This Year | $19.05 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.95 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $0.14 |
| 52 Week High | $29.91 | $12.03 |
| Indicator | EML | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 67.37 |
| Support Level | $24.10 | $6.22 |
| Resistance Level | $27.16 | $7.90 |
| Average True Range (ATR) | 1.36 | 0.41 |
| MACD | -0.25 | 0.04 |
| Stochastic Oscillator | 16.23 | 88.98 |
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to the industrial market. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It has one reportable segment: Engineered Solutions, which provides engineered solutions mainly for the commercial transportation and logistics markets. This segment offers a diverse product line of custom and standard vehicular and industrial hardware, including turnkey returnable packaging solutions, blow molds, compression latches, draw latches, hinges, camlocksaccess, mirrors, and mirror-cameras, among other products. Geographically, the group derives maximum revenue from the United States.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.